The skeletal impact of cancer therapies

Abstract

Both cancer and therapies used in the treatment of cancer can have significant deleterious effects on the skeleton, increasing the risks for both bone loss and fracture development. While advancements in cancer therapies have resulted in enhanced cancer survivorship for patients with many types of malignancies, it is increasingly recognized that efforts to reduce bone loss and limit fractures must be considered for nearly all patients undergoing cancer therapy in order to diminish the anticipated future skeletal consequences. To date, most studies examining the impact of cancer therapies on skeletal outcomes have focused on endocrine-associated cancers of the breast and prostate, with more recent advances in our understanding of bone loss and fracture risk in other malignancies. Pharmacologic efforts to limit the adverse effects of cancer therapies on bone have nearly universally employed anti-resorptive approaches, although studies have frequently relied on surrogate outcomes such as changes in bone mineral density or bone turnover markers, rather than on fractures or other skeletal-related events, as primary study endpoints. Compounding current deficiencies for the provision of optimal care is the recognition that despite clearly written and straightforward society-based guidelines, vulnerable eligible patients are very often neither identified nor provided with appropriate treatments to limit the skeletal impact of their cancer therapies. KEYWORDS androgen deprivation therapy, aromatase inhibitor, bone loss, breast cancer, myeloma, prostate cancer

Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

“…Baseline risks are similar to the general population, including advanced age, female sex, hypogonadism, hyperparathyroidism, rheumatoid arthritis, low body weight, chronic liver or kidney disease, and poor nutrition [16,31,32]. Additional pre-HCT risks may be attributable to underlying disease indications for HCT, like multiple myeloma [33] or sickle cell disease (SCD) [34][35][36], or to pretransplantation therapies for those underlying diseases with chemotherapy or glucocorticoids [37]; special attention should be given to patients with these risks.…”

Effects of Sex and Age on Fat Fraction, Diffusion-Weighted Image Signal Intensity and Apparent Diffusion Coefficient in the Bone Marrow of Asymptomatic Individuals: A Cross-Sectional Whole-Body MRI Study

“…Second, our results are useful to monitor how cancer and cancer therapies affect bone marrow health. Indeed, they both promote the acceleration of bone remodeling process, inducing trabecular resorption and increasing the risks for both bone loss and fracture development [52]. As relative %FF and ADC are being investigated as markers of bone quality [18,19,53], the values measured in this study may be considered a reference for normal bone marrow and could be compared with the values measured in the normal bone marrow of cancer patients undergoing WB-MRI during therapy to assess therapy-induced bone weakening.…”

Morphological Aspects of Reparative Bone Tissue Regeneration under the Influence of Antitumor Chemotherapy

“…Ще до початку лікування раку онкологічні хворі мають підвищений ризик прискореної втрати кісткової тканини, про що свідчить зниження мінеральної щільності кісткової тканини у хворих на рак, незалежно від його типу. Втрата кісткової маси у пацієнтів із злоякісними новоутвореннями відображає як наслідки самого раку, так і скелетну відповідь на терапію, яка в даний час використовується для його лікування, включаючи широкий спектр таких хіміотерапевтичних засобів, як глюкокортикоїди, інгібітори ароматази (ШІ) та стероїдні антиандрогени [9].…”